Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) EBITDA (2019 - 2025)

Avidity Biosciences (RNA) has disclosed EBITDA for 7 consecutive years, with -$236.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA fell 121.97% year-over-year to -$236.3 million, compared with a TTM value of -$685.0 million through Dec 2025, down 114.37%, and an annual FY2025 reading of -$685.0 million, down 114.37% over the prior year.
  • EBITDA was -$236.3 million for Q4 2025 at Avidity Biosciences, down from -$174.5 million in the prior quarter.
  • Across five years, EBITDA topped out at -$23.8 million in Q1 2021 and bottomed at -$236.3 million in Q4 2025.
  • Average EBITDA over 5 years is -$75.4 million, with a median of -$51.4 million recorded in 2023.
  • The sharpest move saw EBITDA tumbled 291.82% in 2021, then decreased 3.24% in 2023.
  • Year by year, EBITDA stood at -$38.7 million in 2021, then fell by 28.36% to -$49.7 million in 2022, then decreased by 17.57% to -$58.4 million in 2023, then tumbled by 82.16% to -$106.5 million in 2024, then crashed by 121.97% to -$236.3 million in 2025.
  • Business Quant data shows EBITDA for RNA at -$236.3 million in Q4 2025, -$174.5 million in Q3 2025, and -$158.3 million in Q2 2025.